Research News for June 2011
-
Medicare Will Continue Paying for Avastin to Treat Metastatic Breast Cancer
Medicare has announced that it will continue to pay for Avastin to treat metastatic breast cancer.
-
Childhood Cancer Treatment Increases Risk of Developing Future Cancer
A study found that people treated for cancer in childhood have a 10% risk of developing a different cancer -- including breast cancer -- later in life.
-
FDA Expert Panel Recommends Removing Breast Cancer Indication from Avastin
An FDA advisory committee unanimously recommended that Avastin should no longer be approved to treat metastatic, HER2-negative breast cancer.
-
Regular Screening Mammograms Save Lives
A large, long-term Swedish study found that regular screening mammograms reduced a woman's risk of dying of breast cancer by 31%.
-
Many Women Who Might Benefit Don’t Get Radiation After Mastectomy
Research shows that nearly half of older women with a higher-than-average risk of breast cancer coming back aren't getting radiation after mastectomy even though they would benefit from it.
-
FDA Silicone Implant Monitoring Program Shows No Increase in Breast Cancer Risk
The FDA reports that there is no evidence that silicone implants increase the risk of breast cancer or autoimmune diseases.
-
FDA Approves New HER2 Test
The FDA has approved a new test to determine the HER2 status of breast cancers.
-
Experimental Dovitinib Seems to Offer No Benefits for Metastatic, HER2-Negative Disease
A very small, very early study found that the experimental targeted therapy dovitinib didn't benefit women diagnosed with metastatic, HER2-negative breast cancer.
-
Adding Tykerb to Herceptin and Chemo Improves Survival in Metastatic, HER2-Positive Disease
Research suggests that treating women diagnosed with metastatic, HER2-positive breast cancer with Tykerb and Herceptin and chemotherapy improves survival compared to only Herceptin and chemotherapy.
-
Obesity Doesn’t Affect Survival in Metastatic Disease
Research has found that being overweight or obese at diagnosis doesn't affect the survival of women diagnosed with metastatic breast cancer.
